Increased levels of 5-HT 1A receptor binding in ventral visual pathways in Parkinson's disease

Movement Disorders

Volumn 27, Issue 6, 2012, Pages 735-742

  Huot, Philippe ^a,b   Johnston, Tom H ^a   Visanji, Naomi P ^c   Darr, Tayyeba ^a   Pires, Donna ^a   Hazrati, Lili Naz ^c   Brotchie, Jonathan M ^a   Fox, Susan H ^a,b  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

5 HT 1A receptors; L dopa; Parkinson's disease; Serotonin; Visual hallucinations

Indexed keywords

1 (2 METHOXYPHENYL) 4 (4 PHTHALIMIDOBUTYL)PIPERAZINE; LEVODOPA; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SEROTONIN 1A RECEPTOR;

ADULT; AGED; ARTICLE; AUTORADIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; GLOBUS PALLIDUS; HUMAN; HUMAN TISSUE; MALE; MOTOR CORTEX; ORBITAL CORTEX; PARKINSON DISEASE; PRIORITY JOURNAL; RECEPTOR BINDING; RETROSPECTIVE STUDY; SUBSTANTIA NIGRA; TEMPORAL CORTEX; THALAMUS; VISUAL HALLUCINATION; VISUAL SYSTEM;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; AUTORADIOGRAPHY; BRAIN; FEMALE; HALLUCINATIONS; HUMANS; LEVODOPA; MALE; PARKINSON DISEASE; RECEPTOR, SEROTONIN, 5-HT1A; VISUAL PATHWAYS;

EID: 84861652848     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24964     Document Type: Article

References (59)

1. Marsden CD. The mysterious motor function of the basal ganglia: the Robert Wartenberg Lecture. Neurology 1982; 32: 514-539.
2. Hornykiewicz O, Kish SJ. Biochemical pathophysiology of Parkinson's disease. Adv Neurol 1987; 45: 19-34.
3. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
4. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-134.
5. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 2009; 24: 1255-1266.
6. Huot P, Fox SH, Brotchie JM. The serotonergic system in Parkinson's disease. Prog Neurobiol 2011; 95: 163-212.
7. Halliday GM, Li YW, Blumbergs PC, et al. Neuropathology of immunohistochemically identified brainstem neurons in Parkinson's disease. Ann Neurol 1990; 27: 373-385.
8. Fahn S, Libsch LR, Cutler RW. Monoamines in the human neostriatum: topographic distribution in normals and in Parkinson's disease and their role in akinesia, rigidity, chorea, and tremor. J Neurol Sci 1971; 14: 427-455.
9. Bernheimer H, Birkmayer W, Hornykiewicz O. [Distribution of 5-hydroxytryptamine (serotonin) in the human brain and its behavior in patients with Parkinson's syndrome]. Klin Wochenschr 1961; 39: 1056-1059.
10. Scatton B, Javoy-Agid F, Rouquier L, Dubois B, Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983; 275: 321-328.
11. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005; 20: 190-199.
12. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005; 20: 130-140.
13. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol 2005; 4: 605-610.
14. Aarsland D, Larsen JP, Tandberg E, Laake K. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study. J Am Geriatr Soc 2000; 48: 938-942.
15. Kempster PA, O'sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133: 1755-1762.
16. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125: 391-403.
17. Goetz CG, Pappert EJ, Blasucci LM, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 1998; 50: 515-517.
18. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J Neural Transm 2004; 111: 1447-1453.
19. Ballanger B, Strafella AP, van Eimeren T, et al. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416-421.
20. Huot P, Johnston TH, Darr T, et al. Increased 5-HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25: 1399-1408.
21. Dupre KB, Ostock CY, Eskow Jaunarajs KL, et al. Local modulation of striatal glutamate efflux by serotonin 1A receptor stimulation in dyskinetic, hemiparkinsonian rats. Exp Neurol 2011; 229: 288-299.
22. Ostock CY, Dupre KB, Eskow Jaunarajs KL, et al. Role of the primary motor cortex in l-DOPA-induced dyskinesia and its modulation by 5-HT1A receptor stimulation. Neuropharmacology 2011; 61: 753-760.
23. Eskow KL, Dupre KB, Barnum CJ, Dickinson SO, Park JY, Bishop C. The role of the dorsal raphe nucleus in the development, expression, and treatment of L-dopa-induced dyskinesia in hemiparkinsonian rats. Synapse 2009; 63: 610-620.
24. Carta M, Carlsson T, Kirik D, Bjorklund A. Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 2007; 130: 1819-1833.
25. Huot P, Johnston TH, Koprich JB, Winkelmolen L, Fox SH, Brotchie JM. Cortical and striatal 5-HT1A receptor levels in dyskinetic and non-dyskinetic MPTP-lesioned macaques. Neurobiol Aging 2012;33:207.e9-e19.
26. Blier P, Ward NM. Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 2003; 53: 193-203.
27. Sargent PA, Kjaer KH, Bench CJ, et al. Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry 2000; 57: 174-180.
28. Toth M. 5-HT1A receptor knockout mouse as a genetic model of anxiety. Eur J Pharmacol 2003; 463: 177-184.
29. Burnet PW, Eastwood SL, Harrison PJ. 5-HT1A and 5-HT2A receptor mRNAs and binding site densities are differentially altered in schizophrenia. Neuropsychopharmacology 1996; 15: 442-455.
30. Bymaster FP, Calligaro DO, Falcone JF, et al. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 1996; 14: 87-96.
31. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000; 68: 29-39.
32. Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC, Jacobs BL. WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: comparison with (S)-WAY-100135. J Pharmacol Exp Ther 1996; 278: 752-762.
33. Fletcher A, Bill DJ, Bill SJ, et al. WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors. Eur J Pharmacol 1993; 237: 283-291.
34. Middleton FA, Strick PL. The temporal lobe is a target of output from the basal ganglia. Proc Natl Acad Sci U S A 1996; 93: 8683-8687.
35. Parent A, Sato F, Wu Y, Gauthier J, Levesque M, Parent M. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 2000; 23( 10 SUPPL): S20-S27.
36. DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol 2007; 64: 20-24.
37. Vonsattel JP, Aizawa H, Ge P, et al. An improved approach to prepare human brains for research. J Neuropathol Exp Neurol 1995; 54: 42-56.
38. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001; 57: 1497-1499.
39. Chemel BR, Roth BL, Armbruster B, Watts VJ, Nichols DE. WAY-100635 is a potent dopamine D4 receptor agonist. Psychopharmacology (Berl) 2006; 188: 244-251.
40. Patel S, Freedman S, Chapman KL, et al. Biological profile of L-745, 870, a selective antagonist with high affinity for the dopamine D4 receptor. J Pharmacol Exp Ther 1997; 283: 636-647.
41. Nakane M, Cowart MD, Hsieh GC, et al. 2-[4-(3, 4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist. Neuropharmacology 2005; 49: 112-121.
42. Rydelek-Fitzgerald L, Teitler M, Fletcher PW, Ismaiel AM, Glennon RA. NAN-190: agonist and antagonist interactions with brain 5-HT1A receptors. Brain Res 1990; 532: 191-196.
43. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967; 17: 427-442.
44. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol. 2005 Sep; 8( 3): 341-56.
45. Newman-Tancredi A, Cussac D, Quentric Y, et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther 2002; 303: 815-822.
46. Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006; 28: 1065-1078.
47. Fox SH, Brotchie JM. 5-HT2C receptor binding is increased in the substantia nigra pars reticulata in Parkinson's disease. Mov Disord 2000; 15: 1064-1069.
48. Huot P, Levesque M, Parent A. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea. Brain 2007; 130: 222-232.
49. Huot P, Levesque M, Morissette M, et al. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys. J Chem Neuroanat 2008; 35: 77-84.
50. Ballanger B, Klinger H, Eche J, et al. Role of serotonergic 1A receptor dysfunction in depression associated with Parkinson's disease. Mov Disord 2011; 27: 84-89.
51. Sharp SI, Ballard CG, Ziabreva I, et al. Cortical serotonin 1A receptor levels are associated with depression in patients with dementia with Lewy bodies and Parkinson's disease dementia. Dement Geriatr Cogn Disord 2008; 26: 330-338.
52. Hall H, Lundkvist C, Halldin C, et al. Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]way-100635. Brain Res 1997; 745: 96-108.
53. Pazos A, Probst A, Palacios JM. Serotonin receptors in the human brain-III. Autoradiographic mapping of serotonin-1 receptors. Neuroscience 1987; 21: 97-122.
54. Frechilla D, Cobreros A, Saldise L, et al. Serotonin 5-HT(1A) receptor expression is selectively enhanced in the striosomal compartment of chronic parkinsonian monkeys. Synapse 2001; 39: 288-296.
55. Mengod G, Vilaro MT, Raurich A, Lopez-Gimenez JF, Cortes R, Palacios JM. 5-HT receptors in mammalian brain: receptor autoradiography and in situ hybridization studies of new ligands and newly identified receptors. Histochem J 1996; 28: 747-758.
56. Lee T, Seeman P, Rajput A, Farley IJ, Hornykiewicz O. Receptor basis for dopaminergic supersensitivity in Parkinson's disease. Nature 1978; 273: 59-61.
57. Shinotoh H, Inoue O, Hirayama K, et al. Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study. J Neurol Neurosurg Psychiatry 1993; 56: 467-472.
58. Aubert I, Guigoni C, Hakansson K, et al. Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Ann Neurol 2005; 57: 17-26.
59. Mai JK, Paxinos G, Assheuer JK. Atlas of the Human Brain. 2nd ed. San Diego, CA: Elsevier Academic Press; 2004.